Appointed
Dr. Gil Aharon
Director
NRXS ·
Neuraxis, INC
the Board appointed Dr. Aharon to the Board, effective January 1, 2025.
Ready 8-Ks
24
Latest filing
April 22, 2026, 7:59 PM ET
Top materiality
0.80
Event mix
other_material ×12 · earnings ×5 · leadership ×2
Sentiment
4 pos · 4 neg · 16 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for NRXS
Highest-materiality recent filing
NeurAxis reports FY2023 net loss $14.6M; restates Q3 2023 due to $3.7M accounting error
- FY2023 revenue $2.5M down 8.4% YoY; net loss widened to $14.6M from $4.8M in 2022.
- Restating Q3 2023 financials: $3.7M understatement of net loss and APIC due to warrant liability misclassification.
-
Neuraxis ups ATM offering to $11.5M after selling 1.125M shares under prior $6.27M program
On Apr 21, 2026, Neuraxis filed a prospectus supplement increasing the ATM offering cap to $11,500,000 from $6,270,000.
-
Neuraxis reports preliminary Q1 2026 net sales of $1.6M, up 77% YoY; operating loss of $1.7M
Cash and cash equivalents ~$7.1M as of March 31, 2026.
-
Neuraxis gets FDA 510(k) clearance for PENFS to treat functional dyspepsia in ages 8+
FDA cleared Neuraxis' PENFS for functional abdominal pain associated with functional dyspepsia and nausea in patients 8 years and older.
-
Neuraxis reports preliminary Q3 net sales $0.8M, operating loss $2.1M
Preliminary unaudited cash and equivalents of $4.4M as of September 30, 2025.
-
Neuraxis enters $3.3M ATM offering agreement with Craig-Hallum
ATM offering of up to $3.3M of common stock at prevailing market prices.
-
Neuraxis ends Masimo partnership on NSS-2 Bridge; pays $200K, forfeits future royalties
Terminated License and Collaboration Agreement with Masimo Corp., effective July 1, 2025.
-
Neuraxis stockholders approve Series B conversion stock issuance; elect directors
Votes to approve issuance of 20%+ of outstanding common stock upon conversion of Series B Preferred Stock passed with 4.1M for, 129K against, 1.1M broker non-votes.
-
Neuraxis posts investor presentation to website; no specific financial details disclosed in filing
Investor presentation covering strategy, performance, and objectives posted to ir.neuraxis.com on May 23, 2025.
-
Neuraxis announces $5.0M registered direct offering of 1.54M shares at $3.25/share
Offering of 1,538,461 shares at $3.25/share; gross proceeds ~$5.0M before fees.
-
Neuraxis settles litigation for $750k payable starting Jan 2026; raises ~$1M from warrant exercises
Settles two lawsuits (Physicians' Litigation and Medical Practice Entities' Litigation) for $750,000 total, payable in 12 equal monthly installments beginning January 2026.
-
NeurAxis preliminary Q4 revenue up 50% YoY to ~$800K; cash $3.7M
Preliminary Q4 2024 revenue ~$800K (+50% YoY); FY2024 revenue ~$2.7M (+11% YoY).
-
Neuraxis appoints Dr. Gil Aharon to board effective Jan 1, 2025
Dr. Gil Aharon appointed to Neuraxis board effective Jan 1, 2025, as designee of investors in recent $5M Series B financing.
-
Increased authorized Series B Preferred shares from 4,000,000 to 5,000,000.
-
Neuraxis raises ~$5M through Series B Convertible Preferred Stock to three investors
Sold 2,100,840 shares of Series B Preferred Stock at $2.38 stated value for aggregate $5M, closed Nov 13, 2024.
-
NeurAxis Q3 revenue up 40% to $667K; operating loss narrows 45%; secures $5M investment
Revenue $667K, +40% YoY; unit sales +50%.
-
Neuraxis cuts Flagstaff investment to $1.8M, raises $145k from new Series B preferred sale
Fourth Amendment reduces Flagstaff SPA total from $5M to $1.8M; $800k received, $1M due by Dec 31, 2024.
-
Neuraxis converts $4.94M of convertible notes into 2.07M Series B Preferred shares
$4,935,001.90 of Preferred Stock Notes automatically converted into 2,073,524 Series B Preferred shares at $2.38/share.
-
Neuraxis shareholders approve expanded equity plan and blank check preferred
All five director nominees elected with 85%–99.99% votes for; quorum of 65.61% achieved.
-
Revenue $611.5K, down 5.3% YoY; gross margin 88.0% vs 89.5%.
-
Three non-employee directors (Ferge, Keyser, Watkins) granted fully vested shares for services through March 31, 2024.
-
Neuraxis raises $3M via convertible notes at 8.5% interest; warrants amended
Issued ~$3M aggregate principal convertible notes to three institutional investors; 8.5% annual interest payable quarterly.
-
Neuraxis COO Dan Clarence terminated; severance through Oct 2024
COO Dan Clarence employment terminated effective April 10, 2024.
-
NeurAxis reports FY2023 net loss $14.6M; restates Q3 2023 due to $3.7M accounting error
FY2023 revenue $2.5M down 8.4% YoY; net loss widened to $14.6M from $4.8M in 2022.
-
Neuraxis increases Flagstaff financing to $5M, replaces preferred with convertible note
Amendment raises Flagstaff investment from $3M to $5M via convertible promissory note.
Executive changes
Departed
Dan Clarence
Chief Operating Officer
NRXS ·
Neuraxis, INC
On April 10, 2024, the employment of Dan Clarence, Chief Operating Officer of NeurAxis, Inc. (the "Company"), terminated effective immediately.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.60 · Most common event other_material